Mechanism of FGF23 processing in fibrous dysplasia

Journal of Bone and Mineral Research

Volumn 27, Issue 5, 2012, Pages 1132-1141

  Bhattacharyya, Nisan ^a   Wiench, Malgorzata ^b   Dumitrescu, Claudia ^a   Connolly, Brian M ^c   Bugge, Thomas H ^c   Patel, Himatkumar V ^d   Gafni, Rachel I ^a   Cherman, Natasha ^a   Cho, Monique ^d   Hager, Gordon L ^b   Collins, Michael T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

FGF23; FIBROUS DYSPLASIA; FURIN; G s ; GNAS; McCUNE ALBRIGHT SYNDROME; OSTEOMALACIA; PHOSPHATE METABOLISM; ppGalNAcT3; PROCESSING; RICKETS

Indexed keywords

CYCLIC AMP; FIBROBLAST GROWTH FACTOR 23; FURIN;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; BONE MARROW STROMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; FIBROUS DYSPLASIA; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PROCESSING; STROMA CELL;

BONE MARROW CELLS; CELL LINE; CYCLIC AMP; FIBROBLAST GROWTH FACTORS; FIBROUS DYSPLASIA OF BONE; FURIN; GENE EXPRESSION REGULATION; HUMANS; N-ACETYLGALACTOSAMINYLTRANSFERASES;

EID: 84859886970     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1546     Document Type: Article

References (34)

1. Quarles LD., Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008; 118: 3820-8.
2. White KE, Larsson TE, Econs MJ., The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev. 2006; 27: 221-41.
3. Prie D, Beck L, Urena P, Friedlander G., Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens. 2005; 14: 318-24.
4. Razzaque MS, Lanske B., The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 2007; 194: 1-10.
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T., Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001; 98: 6500-5.
6. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T., FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19: 429-35.
7. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T., Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002; 143: 3179-82.
8. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87: 4957-60.
9. Imel EA, Hui SL, Econs MJ., FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007; 22: 520-6.
10. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38: 1310-5.
11. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003; 112: 683-92.
12. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE., A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab. 2005; 90: 2424-7.
13. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004; 36: 579-81.
14. Kato K, Jeanneau C, Tarp MA, Benet-Pages A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H., Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006; 281: 18370-7.
15. ADHR C., Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet. 2000; 26: 345-8.
16. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B., An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005; 14: 385-90.
17. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ., Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011; 96: 3541-9.
18. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM., FGF23 is processed by proprotein convertases but not by PHEX. Bone. 2004; 35: 455-62.
19. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG., Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res. 2001; 16: 806-13.
20. Brown WW, Juppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL., Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab. 2009; 94: 17-20.
21. Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, Robey PG., Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Invest. 1998; 101: 1737-44.
22. Zara J, Hagen FK, Ten Hagen KG, Van Wuyckhuyse BC, Tabak LA., Cloning and expression of mouse UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase- T3. Biochem Biophys Res Commun. 1996; 228: 38-44.
23. Albone EF, Hagen FK, VanWuyckhuyse BC, Tabak LA., Molecular cloning of a rat submandibular gland apomucin. J Biol Chem. 1994; 269: 16845-52.
24. Hagen FK, Ten Hagen KG, Beres TM, Balys MM, VanWuyckhuyse BC, Tabak LA., cDNA cloning and expression of a novel UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. J Biol Chem. 1997; 272: 13843-8.
25. O'Connell BC, Tabak LA., Separation of glycopeptides from in vitro O-glycosylation reactions using C18 cartridges. Anal Biochem. 1993; 210: 423-5.
26. Hobson JP, Liu S, Leppla SH, Bugge TH., Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins. Methods Mol Biol. 2009; 539: 115-29.
27. Celi FS, Coppotelli G, Chidakel A, Kelly M, Brillante BA, Shawker T, Cherman N, Feuillan PP, Collins MT., The role of type-1 and type-2 5'deiodinase in the pathophysiology of the T3 toxicosis of McCune-Albright syndrome. J Clin Endocrinol Metab. 2008; 93: 2383-9.
28. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF., Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res. 1997; 12: 2014-23.
29. Semenov AG, Postnikov AB, Tamm NN, Seferian KR, Karpova NS, Bloshchitsyna MN, Koshkina EV, Krasnoselsky MI, Serebryanaya DV, Katrukha AG., Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009; 55: 489-98.
30. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS, Collins MT., Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007; 92: 2374-7.
31. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA. 2010; 107: 407-12.
32. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H., Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010; 95: 578-85.
33. Takaiwa M, Aya K, Miyai T, Hasegawa K, Yokoyama M, Kondo Y, Kodani N, Seino Y, Tanaka H, Morishima T., Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period. Bone. 2010; 47: 256-62.
34. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA. 2011; 108: E1146-55.